|
Video: What is a Stock Split?
|
|
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Co.'s phospholipid drug conjugate (PDC) therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. Co.'s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets. The CLR 1900 Series is being developed for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers. According to our Cellectar Biosciences stock split history records, Cellectar Biosciences has had 3 splits. | |
|
Cellectar Biosciences (CLRB) has 3 splits in our Cellectar Biosciences stock split history database. The first split for CLRB took place on March 07, 2016. This was a 1 for 10 reverse split, meaning for each 10 shares of CLRB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. CLRB's second split took place on July 17, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of CLRB owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 10 share position following the split. CLRB's third split took place on July 22, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of CLRB owned pre-split, the shareholder now owned 1 share. For example, a 10 share position pre-split, became a 1 share position following the split.
When a company such as Cellectar Biosciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Cellectar Biosciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cellectar Biosciences shares, starting with a $10,000 purchase of CLRB, presented on a split-history-adjusted basis factoring in the complete Cellectar Biosciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$360.00 |
|
End price/share: |
$3.03 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.16% |
|
Average Annual Total Return: |
-37.98% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$84.20 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
03/07/2016 | 1 for 10 | 07/17/2018 | 1 for 10 | 07/22/2022 | 1 for 10 |
|
|